ArticleOphthalmology science2026
Genetic and Phenotypic Characterization of a Large Cohort of Patients with BBS1-Retinopathy.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyze the clinical spectrum and natural history of patients with Design: A single-center retrospective, observational cohort study. Patients: Molecularly confirmed patients with bi-allelic disease-causing variants in Methods: Clinical data were extracted from physical and electronic records. Retinal imaging and electrophysiology were analyzed cross-sectionally and longitudinally. Genetic results were reviewed, and the variants assessed. Main Outcome Measures: Molecular genetic testing and clinical findings, including best-corrected visual acuity (BCVA), qualitative and quantitative analyses of retinal imaging, and electrophysiology. Results: Forty-eight patients were identified and assessed longitudinally; 20.8% had isolated retinopathy. The mean age at baseline visit was 28.7 ± 13.7 years, and the mean follow-up was 10.6 ± 7.7 years. The median BCVA was 0.47 logarithm of minimum angle of resolution (LogMAR) (interquartile range 0.3-0.8) at baseline and 1.3 LogMAR (interquartile range 0.7-2.4) at follow-up, with an average decline of 0.05 LogMAR/year. Obesity and polydactyly were the most frequent systemic associations within our cohort. The mean central macular thickness (CMT) at baseline and follow-up was 179.7 ± 43.1 μm and 166.6 ± 50.3 μm. The mean outer nuclear layer thickness (ONLT) at baseline and follow-up was 32.6 ± 21.5 μm and 25.6 ± 22.1 μm. The rate of decline for CMT and ONLT was 4.2 μm and 1.7 μm per year, respectively. When the different genotypes were compared, there was no statistically significant difference between the rates of progression. However, homozygous patients for the most common variant p.(Met390Arg) had an older age of onset and reached legal blindness at an older age compared with the other genotypes. Of the patients who had electrophysiology available, 19 of 27 had rod-cone pattern dysfunction, (6/27) a similar degree of rod and cone dysfunction. One had a cone-rod dystrophy pattern, and the other had only macular dysfunction; both developed a rod-cone pattern during follow-up. Seven Conclusions: This study is a large cohort with long longitudinal follow-up of molecularly confirmed patients with Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.